Company profile
Genprex, Inc. logo

Genprex, Inc.

Pipeline3 assets

  • quaratusugene ozeplasmid (REQORSA)REQORSA / TUSC2 / non-viral gene therapy / Oncology
    EGFR-mutant NSCLC (osimertinib-resistant)Phase 1/2Phase 2a expansion enrollingUnited Statesextensive-stage SCLC (maintenance with atezolizumab)Phase 1/2expansion enrollingUnited States
  • GPX-002GPX-002 / PDX1 and MafA / AAV gene therapy / Diabetes
    Type 1 DiabetesPreclinicalType 2 DiabetesPreclinical
  • NPRL2 gene therapyNPRL2 / non-viral gene therapy / Oncology
    KRAS/STK11 mutant anti-PD1-resistant NSCLCPreclinical

Latest news11 items

All news

Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO Annual Meeting

Trop-2 H-scores Above 100 and PTEN H-scores Below 100 Correlated With Longer Progression Free Survival in Non-Small Cell Lung Cancer Patients Identified Biomarkers May Predict Patient Response, Enable Targeted Patient Selection and Allow for Precision Medicine AUSTIN, Texas — (May 26, 2026) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ:...

Presentation / Abstract • Phase 1/2ASCO abstract release Tue, May 26, 2026

Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting

Pdx1/MafA Gene Therapy Reversed Hyperglycemia in Type 2 Diabetic Models Within Four Weeks AUSTIN, Texas — (May 14, 2026) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators...

Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer

Strengthens Patent Estate and Expands Protection in Another Target Market AUSTIN, Texas — (April 30, 2026) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that The Israel Patent Office (ILPO) has granted...

Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting

Pdx1/MafA Gene Therapy Reversed Hyperglycemia in Type 2 Diabetic Models Within Four Weeks AUSTIN, Texas — (April 28, 2026) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators...

Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy To Be Released at the 2026 ASCO Annual Meeting

AUSTIN, Texas — (April 22, 2026) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators’ abstract has been selected for publication at the upcoming 2026 American Society of Clinical...

Presentation / Abstract

Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting

TROP2 and PTEN Biomarkers May Predict Patient Response to Reqorsa® Gene Therapy REQORSA Induced Apoptosis and Decreased Tumor Volume in ALK-EML4 Positive Translocated Non-Small Cell Lung Cancer Cell Lines and In Vivo Mouse Studies REQORSA Boosts Natural Killer (NK) Cell Antitumor Activity AUSTIN, Texas — (April 20, 2026) — Genprex, Inc....

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting

Research Collaborators Identify Biomarkers that May Predict Patient Response to Reqorsa® Gene Therapy REQORSA is a Potential Treatment for ALK-EML4 Positive Translocated Non-Small Cell Lung Cancer REQORSA Boosts Natural Killer (NK) Cell Antitumor Activity AUSTIN, Texas — (March 18, 2026) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ:...

Genprex to Participate at BIO Europe Spring 2026

AUSTIN, Texas — (March 10, 2026) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that members from its executive leadership team will be attending and participating at BIO Europe Spring taking place March...

Genprex, Inc. • Endpoint Arena